NASDAQ · Biotechnology

Neurogene Inc. (NGNE) Stock

$26.40 -0.38% NASDAQ: NGNE Healthcare

Valuation

MetricValue
Price$26.40
Market Cap$417.18M
P/E Ratio-4.80
P/B Ratio2.75
P/S Ratio0.00
EPS (TTM)$-4.24
52-Week High$43.66
52-Week Low$15.93
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-45.11%
ROA-45.47%
ROCE-54.45%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.04
Current Ratio17.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-51.0M$-57.0M$-56.0M$-83.0M$-103.0M
Net Profit$-51.0M$-55.0M$-36.0M$-75.0M$-90.0M
EPS$-0.92$-4.30$-2.83$-4.28$-4.24
Op Margin———-8930.3%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$101.0M$109.0M$223.0M$336.0M$289.0M
Total Liabilities$193.0M$11.0M$37.0M$25.0M$24.0M
Cash$71.0M$82.0M$148.0M$137.0M$104.0M
Borrowings$6.0M$5.0M$16.0M$12.0M$10.0M

Latest News

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 6, 2026 Neurogene Prices $125 Million Public Offering MT Newswires · Jul 1, 2026 Neurogene Inc. Announces Pricing of $125 Million Public Offering Business Wire · Jul 1, 2026 Neurogene Launches Public Offering MT Newswires · Jun 30, 2026 Neurogene Inc. Announces Proposed Public Offering Business Wire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-46.0M$-53.0M$-51.0M$-71.0M$-77.0M
Investing Cash Flow$-37.0M$-4.0M$25.0M$-126.0M$13.0M
Financing Cash Flow$0$0$0$-5.0M$0
Net Cash Flow$-14.0M$11.0M$67.0M$-12.0M$-33.0M
Free Cash Flow$-65.0M$-55.0M$-52.0M$-71.0M$-78.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.27
EV / EBITDA-2.95
FCF Yield-20.83%
Quick Ratio10.64
Interest Coverage-60673.00
Return 1Y54.05%
Return 3Y158.13%
Return 5Y-76.63%

Ownership

Insiders Held7.07%
Institutions Held88.49%
Institutions Float Held95.23%
Institutional HolderSharesReport Date
Samsara BioCapital, LLC1,717,1272026-03-31
Redmile Group, LLC1,459,5992026-03-31
Casdin Capital, LLC1,420,3612026-03-31
RTW Investments LP1,362,4562026-03-31
EcoR1 Capital, LLC1,271,3422026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALECAlector, Inc. $2.08 +2.97% -1.84 $230.93M 0.00%
DSGNDesign Therapeutics, Inc. $11.65 +1.39% -10.46 $727.62M 0.00%
FDMT4D Molecular Therapeutics, Inc. $13.33 +4.96% -5.03 $696.84M 0.00%
LXEOLexeo Therapeutics, Inc. $3.23 +0.62% -3.07 $253.62M 0.00%
MGTXMeiraGTx Holdings plc $10.69 +1.81% 17.43 $990.00M 0.00%

About Neurogene Inc.

Neurogene Inc. is led by CEO Rachel L. McMinn, employs 107 people, headquartered in US, publicly traded since 2014.

Neurogene Inc. (NGNE) stock trades at $26.40 with a market capitalization of $417.18M. The stock is valued at a price-to-earnings (P/E) ratio of -4.80, price-to-book of 2.75, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $15.93 and $43.66, and currently trades 39.5% below its 52-week high.

On profitability, Neurogene Inc. generates a return on equity (ROE) of -45.11%, return on capital employed of -54.45%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides